deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT04915729

A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (ORIGINAL)

A Phase III Multi-centre, Prospective, Randomised, Open Label, Blinded Endpoint (PROBE), Active-controlled Parallel Group Trial to Assess Efficacy and Safety of Tenecteplase Versus Alteplase in Chinese Patients With Acute Ischaemic Stroke Within 4.5 Hours After Stroke Onset

Sponsor: Boehringer Ingelheim

Conditions Stroke
Interventions alteplase tenecteplase
Updated 31 times since 2021 Last updated: Dec 6, 2024 Started: Jun 22, 2021 Primary completion: Oct 8, 2023 Completion: Oct 8, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Stroke, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 31 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

31 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Jan 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Jan 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 26 earlier versions

  1. Dec 2023 — Jan 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  7. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  8. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  9. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE3

  10. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  11. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  12. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  13. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  14. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  15. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  16. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  17. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  18. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  19. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  20. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  21. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  22. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE3

  23. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  24. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  25. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  26. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baotou, China , Beijing, China , Changchun, China , Changsha, China , Chifeng, China , Chongqing, China , Dalian, China , Daqing, China , Dongying, China , Guangzhou, China and 31 more locations